Opioid-induced or pain relief-reduced symptoms in advanced cancer patients? by Mercadante, S. et al.
www.EuropeanJournalPain.com
European Journal of Pain 10 (2006) 153–159Opioid-induced or pain relief-reduced symptoms
in advanced cancer patients?
Sebastiano Mercadante a,b,*, Patrizia Villari a, Patrizia Ferrera a, Alessandra Casuccio c
a Anesthesia & Intensive Care Unit and Pain Relief & Palliative Care Unit La Maddalena Cancer Center,
Via San Lorenzo Colli 312, 90146 Palermo, Italy
b Intensive Care and Emergency, Universita` di Palermo, Italy
c Universita` di Palermo, Italy
Received 30 June 2004; accepted 17 February 2005
Available online 28 March 2005Abstract
Background: While opioids in increasing doses may produce adverse eﬀects, the same adverse eﬀects may be associated with poor
pain control. Moreover, in the clinical setting symptomatic treatment and illness may balance the outcome of opioid titration. Some
adverse eﬀects may tend to disappear continuing the treatment in a long-term period.
Aims: The aim of this study was to monitor the eﬀects of a rapid opioid titration combined with symptomatic treatment in patients
with poor relief and to monitor these changes in the following period of 20 days.
Methods: A consecutive sample of 35 patients admitted to an acute Pain Relief and Palliative Care Unit were titrated with opioids,
according to a department policy, allowing administration of parenteral opioids to assist opioid titration with oral or transdermal
opioids.
Results: Thirty-three patients were followed up for the period of the study. Pain was adequately controlled and doses were opioid
doses were stable after a mean of 40 h. Opioid escalation index (OEI) was extremely high initially, and then progressively declined at
the following study intervals. Weakness and nausea and vomiting did not change, as well as confusion and appetite. Drowsiness,
constipation and dry mouth signiﬁcantly increased and then did not change, although a signiﬁcant decrease in drowsiness was sub-
sequently observed. Well-being improved some weeks after opioid stabilization. In multivariate analysis, drowsiness and dry mouth
were correlated to opioid doses.
Conclusion: The eﬀects reported were often due to multiple causes. A rapid decrease in pain intensity induced by rapid opioid titra-
tion does not produce changes in weakness, nausea and vomiting, appetite. While constipation appears the most relevant problem,
resistant to common symptomatic treatment, drowsiness initially produced by acute opioid dose increase and the achievement of
pain relief, tends to spontaneously decrease, probably as the result of late tolerance. Improved well-being may be the late positive
eﬀect of pain relief, also inﬂuenced by the setting of home care.
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dante).1. Introduction
Pain is one of the most feared consequences of
cancer. Opioids are the mainstay of cancer pain manage-
ment, but successful pain management with opioidsAssociation for the Study of Pain. Published by Elsevier Ltd. All rights
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excessive adverse eﬀects. Controversies exist about the
global eﬀect of opioid therapy. Patients on opioids
may have more symptoms than patients not taking opi-
oids (Grond et al., 1994), most patients with severe can-
cer pain may develop other associated symptoms, which
are commonly induced by opioids per se, and intensity
of pain has been found to be associated with a low level
of function and higher intensity of symptoms (Grond
et al., 1994; Klepstad et al., 2000a). Pain control may
indirectly improve some symptoms and other measures,
such as nausea and vomiting, well-being, mood, and
appetite. Fatigue and loss of appetite were correlated
with pain intensity (Klepstad et al., 2000a). While opioid
titration may induce nausea and vomiting, visceral pain
can be associated with vegetative responses, resulting in
vomiting. An improved pain control may blunt these re-
sponses and as a consequence, reduce the frequency and
intensity of gastrointestinal symptoms or improve appe-
tite. Moreover, pain control may improve mood and
well-being, whereas increasing dose of opioids may re-
duce the functional activities, and, as a consequence
mood and well-being sensation. The global picture is
also inferred by the progression of disease, which may
induce some symptoms or inﬂuence some parameters
in a long-term period.
Several studies report that opioid treatment is com-
plicated by adverse eﬀects. However, these studies have
evaluated cancer patients receiving long-term treatment
and were not designed in order to distinguish between
strictly opioid-induced symptoms and symptoms related
to other causes, or to provide possible beneﬁts of pain
relief by opioids on symptom control on a short-term
basis (Cherny et al., 2001; Grond et al., 1996; Merca-
dante, 1999). Attempts have been recently done in pa-
tients titrated with oral morphine after they had
received weak opioids. However, patients were switched
with a relatively low level of pain intensity; therefore it
was not possible to detect the possible eﬀects of a dra-
matic change in pain intensity (Klepstad et al., 2000b).
The aim of this study was to evaluate the clinical
changes produced by the achievement of pain control
in advanced cancer patients, regardless of the opioid
dose required, in the acute setting of opioid titration.
The secondary outcome was to monitor these changes
chronically, to establish the long-term beneﬁts of this
condition after stabilization and the inﬂuence of other
factors, such as the development of tolerance to adverse
eﬀects.2. Patients and methods
Thirty-ﬁve consecutive advanced cancer patients
with uncontrolled pain requiring strong opioids were
scheduled for a prospective longitudinal study. Patientswith an expected survival less than one month and a
Karnofsky status less than 50 were excluded. All
patients were admitted to a Pain Relief and Palliative
Care Unit and were subsequently followed at the
outpatient pain clinic or at home by frequent phone
contacts. Informed consent was obtained, as well as
Institutional approval for the treatment, which is a
standard practice in this Unit.
The type of opioids and the route of administration
were continued, if considered indicated and feasible, or
changed according to the clinical needs, and doses were
titrated to adequate pain relief or dose-limiting toxicity.
Opioids were also given by intravenous route for treat-
ing breakthrough pain episodes and to assist and facili-
tate the dose ﬁnding in patients receiving slow release
morphine and transdermal fentanyl. Doses were chan-
ged on daily basis or more frequently, when required.
For transdermal fentanyl doses could be changed on a
daily basis (Korte et al., 1996). This approach was
allowed by continuous and strict nurse surveillance,
and by providing frequent medical rounds per day.
The use of other drugs, such as adjuvants, was consid-
ered, as well as all the general treatment commonly used
in palliative care (laxatives, etc.) for treating symptoms
eventually occurring.
Pain intensity and well being sensation were moni-
tored using a numerical scale from 0 to 10. Symptoms
associated to opioid therapy or commonly present in ad-
vanced cancer patients, such as nausea and vomiting,
drowsiness, confusion, xerostomy and so on, were rated
using a scale from 0 to 3 (not at all, slight, a lot, awful).
Constipation was evaluated as follows: 0 = stool in the
previous 24 h; 1 = 2 days before; 2 = 3 days before;
3 = four or more days before, or need for clyster. These
data were collected as part of clinical management on a
standard sheet routinely used. For mood it was used a
simple scale: 0 = normal, 1 = some depressed, 2 = mod-
erately depressed, 3 = severely depressed; and for appe-
tite: 0 = normal, 1 = lightly decreased, 2 = moderately
decreased, 3 = absent. Symptoms were assessed by the
patients, assisted by nurses. Data were recorded at
admission (T0), at the end of dose titration, when pain
intensity was considered acceptable by patients (less
than 4/10) and opioid doses were unchanged for
24–48 h (Tx), and 10 days after (T10), and 20 days after
(T20), when all patients were at home.
The pain syndromes were considered on the basis of
clinical history, anatomical site of primary tumor and
distant metastases, physical examination, investigations
such as CT-scan, MNR and so on, when necessary. Opi-
oid escalation index per cent (OEI%) was calculated at
ﬁxed in advance intervals. This score expresses the mean
increase of opioid dosage per cent from opioid starting
dose (OSD), according the following formula:
[(OMD  OSD)/OSD]/days · 100, where OMD is the
maximal dose of opioid. Opioid escalation index in mg
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dosage in mg using the following formula:
(OMD  OSD)/days. The meaning of this score, im-
proved by this formula, has been discussed in previous
studies (Mercadante et al., 1997).
To facilitate the calculations, opioid doses were
expressed as oral morphine equivalents, by using ratios
commonly employed in the Unit: morphine 60 mg =
transdermal fentanyl 0.6 mg = methadone 12 mg.
Given the open design of the study, an independent
observer was asked to establish from available clinical
data, if symptoms were induced by opioid escalation
or there were other possible causes.
2.1. Statistical analysis
Frequency analysis was performed with chi-square
test. The paired Wilcoxon signed-rank test and paired
samples Students t-test were used to compare symptom
intensity and opioid dosage, respectively, at the diﬀerent
intervals. The one-way analysis of variance (ANOVA)
and Mann–Whitney U statistic test were used to evalu-
ate diﬀerence in age groups and gender. The multivari-
ate analysis was performed by MANOVA test. All
p-values were two-sided and p-values less than 0.05 were
considered statistically signiﬁcant.3. Results
The mean age of patients surveyed was 58.9 years (CI
95% 54–63). Fifteen patients were women. Thirty-three
patients completed the study. Two patients died beforeTable 1
Pain intensity and well being (scale 0–10), symptoms and other variables ex
morphine equivalents (mg). Patients who presented a symptom intensity of
T0 Tx T1
Pain intensity 7.11 (6.26–7.97) 2.34 (1.82–2.87)*** 3.0
Well-being 4.80 (3.90–5.70) 5.06 (4.11–6.01) 5.5
Nausea-vomiting 0.66 (0.38–0.93) 0.51 (0.27–0.76) 0.5
Drowsiness 0.40 (0.21–0.59) 1.0 (0.76–1.24)*** 0.8
Weakness 1.0 (0.76–1.24) 1.03 (0.78–1.28) 0.9
Confusion 0.14 (0.0–0.29) 0.26 (0.1–0.4) 0.3
Dry mouth 0.77 (0.49–1.05) 1.03 (0.80–1.26) 0.7
Constipation 0.77 (0.41–1.14) 1.11 (0.71–1.52)* 1.0
Appetite 0.71 (0.13–1.30) 0.74 (0.52–0.97) 0.5
Mood 0.69 (0.50–0.87) 0.60 (0.41–0.79) 0.4
Opioid doses 113 231 (154–307) 191
OEI mg 59 (20–102) 7.8
OEI% 52 (18–97) 6.9
T0 = data recorded at admission, Tx = data recorded at the end of opioid
recorded 20 days after admission (see text).
a p < 0.05 versus Tx.
b p < 0.0005 versus Tx.
* p < 0.05 versus T0.
*** p < 0.0005 versus T0.completing the study (one before T10, and the other
one before T20). Death was unexpected in relation to
the previous visit-phone contact or Karnofsky status.
Pain mechanisms were somatic in 17 patients, mixed
(visceral/somatic and neuropathic) in eight patients, vis-
ceral in seven patients, and pure neuropathic in one pa-
tient. Twenty-ﬁve patients had severe pain (7 or more on
a numerical scale 0–10). At admission six patients were
on non-opioid analgesics, six patients on tramadol, 13
patients on transdermal fentanyl (mean oral morphine
equivalents 177 mg), seven patients on morphine (mean
oral morphine equivalents 171 mg) and three patients on
methadone (mean oral morphine equivalents 441 mg).
No signiﬁcant changes in Karnofsky status were found
during the period of study. Tx, deﬁned as time when
pain was adequately controlled with stable doses of opi-
oids, occurred 40 h (range 24–68 h) after admission on
average. Although pain levels signiﬁcantly decreased
some hours after starting opioid titration, it was decided
to evaluate the time when the pain intensity was optimal
for patients and opioid dose was stable. In three patients
opioid doses, initially increased were then reduced. OEI
was extremely high at Tx, and progressively declined at
the following study intervals. Patients were discharged
home within a mean of 4.7 days (range 2–7 days).
The pain mechanism did not signiﬁcantly inﬂuenced
OEI and pain or symptom intensity. Data regarding
pain, symptoms, and other variables examined are listed
in Table 1. Pain intensity statistically decreased at Tx,
and adequate pain control was maintained for the next
20 days, while maintaining similar opioid doses. Opioid
doses at the end of titration were relatively large present-
ing an OEI of 59 mg per day, which is extremely higheramined (scale 0–3), expressed as mean (CI 95%), opioid dose in oral
2–3 (scale 0–3, see text)
0 T20 Symptom frequency
at intensity 2–3/3
6 (2.50–3.62)***,a 2.82 (21.8–3.45)***
3 (4.43–6.63)* 5.36 (4.20–6.53)*
3 (0.28–0.78) 0.45 (0.2–0.67) 9
8 (0.69–1.07)*** 0.76 (0.56–0.96)*,a 6
4 (0.67–1.20) 0.84 (0.53–1.16) 10
5 (0.14–0.56) 0.30 (0.10–0.51) 3
6 (0.57–0.96)a 0.73 (0.52–0.93)a 8
(0.58–1.42) 1.03 (0.62–1.44) 12
9 (0.36–0.82) 0.61 (0.36–0.86) 6
4 (0.27–0.62)*,a 0.52 (0.31–0.72) 2
(120–270)* 224 (205–429)
(3.1–12)b 5.5 (2–7.9)b
(3–11.8)b 4.9 (2.1–8)b
titration, T10 = data recorded 10 days after admission, T20 = data
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patients (Mercadante et al., 1997). Opioid doses were
relatively stable at the following intervals. As a conse-
quence OEI calculated at the following intervals dra-
matically decreased (Table 1). The symptom more
frequently assessed as moderate to severe at admission
was weakness, which remained at the same level of
intensity after titration and at the following intervals ta-
ken into consideration, with a tendency to decrease in
time. No signiﬁcant changes in nausea and vomiting,
confusion, and appetite were observed. Nausea and
vomiting and confusion of signiﬁcant intensity were
attributed to disease in four and one patients, respec-
tively. Drowsiness intensity signiﬁcantly increased at
Tx, and the other intervals, although tended to decrease
at T20. In one patient, a possible concomitant contribu-
tion of brain metastases and anticonvulsant drugs, de-
spite other cognitive functions were acceptable, was
suggested by the external reviewer. Dry mouth intensity
initially tended to increase, and then to maintain similar
levels for the period of study. Several concomitant
causes of dry-mouth were assessed by the external re-
viewer, including dehydration, other medication, and
mucositis in three, four and two patients, respectively.
Constipation intensity signiﬁcantly increased at Tx,
and then was maintained at the same level. Other med-
ications, including anticonvulsants, diuretics, and gas-
troprotective drugs, were considered as pre-existing
causes of constipation in seven patients. Other contrib-
uting factors, such as metabolic alterations, dehydra-
tion, reduced physical activity, were identiﬁed in six
patients. Well-being improved at T10 and T20, that is
some weeks after achievement of analgesia. However,
mood occasionally decreased at T10. The occurrence
of opioid-related adverse eﬀects was managed with usual
symptomatic treatments. Laxatives, including lactulose
and senna, were used routinely. Symptomatic drugs
more commonly used are reported in Table 2. In multi-
variate analysis, drowsiness and dry mouth were corre-
lated with the opioid doses (p < 0.0005 and 0.01,
respectively). Although 11 patients clearly improved
their well-being, and in spite of a trend of correlation be-
tween improved well-being and decrease in drowsiness,
no signiﬁcant correlation was found with all other vari-
ables examined.Table 2
Principal symptomatic drugs used during opioid titration
Drugs Pts
Laxatives 33
Steroids 16
Non-opioid analgesics 15
Antiemetics 9
Anticonvulsants 6
Gastroprotectors 174. Discussion
4.1. General considerations
Patients with severe pain require an aggressive treat-
ment, expecially if they are reporting high levels of pain
likely due to poor previous treatment. Timeliness is of
paramount importance in these circumstances. Rapid
opioid titration, either by oral and/or parenteral route,
is advisable, to avoid unnecessary suﬀering. Morever,
pain is known to be associated with poor well-being sen-
sation, decreased appetite, and nausea, and a rapid pain
relief may improve some symptoms associated with pre-
vious uncontrolled pain. Few studies have dealt with the
outcome of pain intervention in patients with severe
pain, particularly regarding the consequence of opioid-
related adverse eﬀects. In cancer patients with uncon-
trolled pain on weak opioids, morphine titration was
successful and achieved quickly, with a threefold mor-
phine dose variation and with a little increase in adverse
eﬀects. Morphine titration took a mean of 2.3 days, and
all patients were stabilized about 6 days after starting
morphine. However, these patients had a relatively good
pain control (32 mm on VAS), thus the changes of
symptoms may be irrelevant (Klepstad et al., 2000b).
In an acute setting, pain intensity decreased 14–24 h
after the initial pharmacological treatment. Patients
had variable levels of pain intensity, and severe
pain was assessed in 20% of patients, with excruciating
pain recorded in three patients. In patients with
severe pain opioids were prescribed over the phone, be-
fore consultation.The eﬀects reported were the result of
a therapeutical adjustment, regarding route and drug
changes, but opioid doses were not provided, and symp-
tom recording was limited to the ﬁrst 24 h (Manfredi
et al., 2000). For these reasons data reported in previous
studies are not comparable with the design used in this
study. Patients with severe pain received an aggressive
treatment with escalating doses of opioids, either orally
or transdermally assisted by parenteral opioids. This is
consistent with the high OEI reported at Tx. While this
is more likely to produce a more rapid analgesia, it can
also to induce a ‘‘jerk’’ in opioid-related symptoms. In
this study, most patients achieved an adequate pain re-
lief within 2 days with a mean dose of oral morphine
equivalents of 231 mg, and are not comparable with
other softer titrations with oral morphine presented in
other studies (Klepstad et al., 2000b). Like pain inten-
sity, opioid doses did not signiﬁcantly increased in the
following period.
The occurrence of adverse eﬀects may limit opioid
escalation, so they are the most important part of the
concept of opioid responsiveness (Mercadante and
Portenoy, 2001; Portenoy et al., 1990). Of interest, in
the present study, the intensity and the frequency of ad-
verse eﬀects were not the result of the spontaneous
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quence of the balanced eﬀect of opioids and illness, and
the concomitant symptomatic treatment, which could
not be withhold for obvious ethical reasons. This corre-
sponds to the raw clinical scenario where adverse eﬀects
occur with a certain intensity to require symptomatic
treatment. To reproduce a standard clinical situation,
antiemetics and adjuvant analgesics were used in some
circumstances to better tolerate opioid eﬀects and
improve analgesia, avoiding to use strict protocol limita-
tions. Laxatives were routinely administered. Symptoms
were relatively controlled by using these measures, de-
spite the high OEI.
Few studies have dealt with the indirect eﬀects of a
signiﬁcant decrease in pain intensity on other variables,
including symptoms. A low increase of adverse eﬀects
was associated when starting morphine after weak opi-
oids were unsuccessful. However, this could reﬂect the
characteristics of population chosen, having relatively
low level of pain intensity, although a threefold opioid
increase was reported (Klepstad et al., 2000a,b). Adverse
eﬀects were acceptable even in an acute setting where
opioids were prevalently given by intravenous route
(Manfredi et al., 2000). The number of opioid attribut-
able adverse eﬀects did not increase over about a 3-week
period. However, follow-up study assessment was done
at weekly intervals, and data during opioids titration
were lacking (Chang et al., 2002).
4.2. Speciﬁc adverse eﬀects
Central nervous system adverse eﬀects are commonly
reported in patients receiving opioids. Drowsiness is ob-
served in 20–60% of patients receiving oral morphine
(Cherny et al., 2001). The symptom more frequently ob-
served during titration was drowsiness, which persisted
for 10 days, and then decreased at the end of the study,
concluded 20 days after, in comparison to the end titra-
tion point (Tx). Considering that opioid doses did not
change in the meantime, this means that such dose esca-
lation required relatively more time to induce some tol-
erance to this adverse eﬀect. The time course of opioid
tolerance to some adverse eﬀects has never been estab-
lished after acute opioid titration with relatively high
doses. Unless for one patient, drowsiness observed in
this study was exclusively due to opioid eﬀects, as no
particular symptomatic treatment was used for this
symptom, due to unavailability of a such type of drugs
in most European countries. The only method used to
limit drowsiness intensity was a more accurate balance
between opioid dose and eﬀect. As the symptom was
largely distributed in all the patients, the intensity was
acceptable in most cases, only six patients presenting
moderate or severe drowsiness. In a previous study,
the number of patients presenting sedation increased
when passing from weak opioids to escalating doses ofmorphine, the values not changing in the subsequent
days when immediate release morphine was substituted
with the slow release preparation at the same doses.
However, this eﬀect was reported in a short-term period,
probably insuﬃcient to reproduce the delayed eﬀects of
tolerance (Klepstad et al., 2000b). In a study on the out-
come of cancer pain consultation, severe drowsiness was
not reported after achieving rapid pain relief in an acute
setting, although methylphenidate was added to the
therapeutical regime in some patients (Manfredi et al.,
2000).
Mild cognitive impairment is common after the initi-
ation of opioid therapy or dose escalation (Bruera et al.,
1989), although there is no data on the prevalence of se-
vere delirium (Cherny et al., 2001). Only three patients
rated as moderate to severe confusion during opioid
titration. This eﬀect was treated by braking opioid esca-
lation or administering symptomatic drugs (the use of
haloperidol is included in the list as an antiemetic). Con-
fusion can be also the consequence of poor pain control,
rather than being induced by opioid titration. In another
acute setting, minimal changes were observed in fre-
quency of delirium after adjusting opioid therapy or
changing route of opioid administration (Manfredi
et al., 2000).
Data from prospective studies indicate that chronic
nausea is observed in 15–30% of patients receiving oral
morphine for chronic cancer pain (Cherny et al.,
2001). However, gastrointestinal symptoms can be
dependent on progression of disease and numerous fac-
tors, including primary diagnosis and concomitant med-
ications. It is diﬃcult to distinguish the prevalent causes
during a long-term treatment, as conﬁrmed by possible
concomitant factors reported in this study. Nausea
and vomiting did not change during titration and re-
mained at acceptable level, probably as the result of
antiemetic medications. Only nine patients had an inten-
sity level requiring speciﬁc treatment, speciﬁcally attrib-
utable to opioids. Thus, this symptom can be managed
during opioid titration in most cases, although this does
not exclude that individual patients be particularly sen-
sible to opioids and resistant to symptomatic treatment.
This was conﬁrmed also in an acute setting, where nau-
sea and vomiting were more frequent before consulta-
tion than after achieving pain control, 12–24 h after
starting the treatment (Manfredi et al., 2000), and when
starting oral morphine, either when using immediate or
sustained-release preparation (Klepstad et al., 2000b,
2003).
Chronic constipation is observed in 40–70% of pa-
tients receiving oral morphine for chronic cancer pain
(Cherny et al., 2001). Constipation signiﬁcantly increased
during opioid titration, despite available standard symp-
tomatic treatment, principally based on senna and lactu-
lose. However, other concomitant causes, particularly
the use of other medications, were also screened from
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rately monitored in the short as well as long-term period
and more eﬀective treatments are needed.
Although the level of dry-mouth tended to increase,
not signiﬁcantly, during opioid titration, then it re-
mained at the same level. While it does not exclude that
the symptom may be acutely induced and maintained by
opioids, the many causes of dry-mouth observed, such
as concomitant medication, dehydration, mucositis, fre-
quently reported in advanced cancer patients, make a
clear relationship with opioid treatment diﬃcult to
prove in the clinical setting.
Opioids, as the spontaneous course of the illness, may
induce weakness. It was the symptommore frequently as-
sessed at admission. However, weakness did not change
during opioid escalation phase and after achieving pain
control. Therefore, it can be supposed that the possible
eﬀect of opioids was balanced by the better physical con-
dition fostered by pain control, or that weakness was
dependent on the previous status of the illness.
Start of morphine treatment in patients switched
from weak opioids had no major inﬂuence on aspects
of health-related quality of life, other than pain (Klep-
stad et al., 2000a). A progressive increase of well-being
was recorded, particularly after discharge. Signiﬁcant
well-being was perceived 10–20 days after opioid titra-
tion, probably as a consequence of a better tolerance
to the drug regimen, which did not change signiﬁcantly.
This can also be the consequence of home care setting,
as well as an improved tolerance to opioids, not neces-
sarily due to the achievement of pain relief, as no corre-
lation was found with this item. Loss of appetite may be
inﬂuenced by poor pain control (Klepstad et al., 2000a),
or by opioid-induced adverse eﬀects, such as nausea,
drowsiness, and weakness. Steroids had been or were
administered in about half of patients for weakness
and poor appetite, although no single indication was
identiﬁed. Appetite was not aﬀected by either OEI or
achievement of pain relief. Changes in mood levels were
diﬃcult to ascertain, as reported in other experiences
(Manfredi et al., 2000), and were not related with well-
being. These data are diﬃcult to interpretate and dem-
onstrate how complex are the factors implicated in
mood and appetite, typically inﬂuenced by the psycho-
logical sphere and the social context. Given these
diﬃculties encountered in the clinical setting, any rela-
tionship with pain relief and OEI was impossible to
demonstrate. In any case no worsening of these symp-
toms attributable to opioids was detected.
In this study other more frequently used tools for
measuring quality of life (Klepstad et al., 2000a) would
have provided more information, but they were not used
to avoid a further burden in quite distressed patients.
The use of questionnaires with at least 30 items was
not considered feasible in this kind of population. This
was a preliminary choose, suggested by previous experi-ence in our setting, where more sophisticated instru-
ments were not accepted by patients or data provided
were imprecise due to lack of collaboration, also inﬂu-
encing the informed consent for carrying on the study.
Therefore, a minimal set was used to gather information
on global well-being, appetite, and mood, other than the
symptoms regularly assessed for monitoring the
patients.5. Conclusion
Data reported in this study are the results of a typical
raw clinical scenario presenting in the setting of an acute
pain relief and palliative care unit, where patients with
severe pain, uncontrolled for prolonged periods of time,
are admitted on emergency basis to provide pain relief
as soon as possible. Opioid titration in patients with se-
vere pain allows a rapid pain control, without interfer-
ring signiﬁcantly with most symptoms, using available
symptomatic therapy. The eﬀects reported are never
due exclusively to opioids in this clinical setting, but
the consequence of concomitant and symptomatic
drugs, actual physical function, and cancer disease per
se. This explains the diﬀerences in frequencies of
opioid-related symptoms reported in literature. Consti-
pation appears the most relevant problem, persisting
in time. Weakness is not aﬀected by opioid titration gi-
ven for achieving optimal pain control. Nausea and
vomiting, which are frequently feared symptoms, are
eﬀectively controlled by available symptomatic drugs,
and do not represent a particular limit in even rapid opi-
oid titration. It is likely that in some cases pain control
may reduce these symptoms. The increase in intensity of
drowsiness, expected after achieving pain relief, as a
consequence of opioid dose increases, but also of a more
relaxing situation in patients previously suﬀering for
poor pain control, tended to slowly decrease in time,
probably due to the occurrence of tolerance, which
can take some weeks to develop after a sharp increase
in opioid dose. Well-being may be the late positive eﬀect
of pain relief, probably inﬂuenced by the setting of home
care, or even by the reduction of drowsiness.
It was diﬃcult to establish a clear eﬀect of opioids on
mood and appetite, due to methodological limits in the
clinical context, where other factors may have a role.
Other studies with appropriate design should assess
the eﬀects of opioids titration using diﬀerent opioids,
route of administration, or treatment schedules.References
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